New drug cocktail shows promise against tough pancreatic cancer
NCT ID NCT06266143
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed phase 1/2 trial tested an experimental drug called Y101D combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for 71 people with advanced pancreatic cancer. The goal was to find a safe dose and see if the combo helps shrink tumors. Results will show whether this approach is worth testing in larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Y101D (an experimental drug) combined with gemcitabine and nab-paclitaxel (standard chemotherapy)
What this could lead to
If successful, this combination could offer a new first-line treatment option for advanced pancreatic cancer, potentially improving tumor shrinkage and survival.
What could go wrong
This is an early-phase trial with only 71 patients, so results may not apply broadly. The added drug Y101D could increase side effects without clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China